Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#17 / 17 Total
XCUR - Exicure Inc - Stock Price Chart
TickerXCUR [NASD]
CompanyExicure Inc
CountryUSA
IndustryBiotechnology
Market Cap4.49MEPS (ttm)1.28
P/E0.41EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y55.67%
P/S0.19EPS next 5Y-
P/B0.46EPS Q/Q58.78%
Dividend-Sales Q/Q-100.00%
Insider Own12.91%Inst Own3.94%
Insider Trans-75.28%Inst Trans-0.96%
Short Float1.75%EarningsMay 16/a
Analyst Recom3.00Target Price2.00
Avg Volume34.41K52W Range0.36 - 1.50
Today 04:08PM Exicure, Inc. Reports Third Quarter 2023 Financial Results (Business Wire)
Apr-22-24 04:01PM Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K (Business Wire)
Feb-06-24 07:05AM Exicure and Bluejay sign hepatitis treatment development deal (Pharmaceutical Business Review) +27.59%
Feb-05-24 04:01PM Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis (Business Wire)
Dec-08-23 08:40AM Why Is Exicure (XCUR) Stock Up 57% Today? (InvestorPlace) +28.59%
Nov-28-23 04:01PM Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q (Business Wire)
Aug-23-23 09:48AM Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors (Business Wire)
Aug-11-23 04:01PM Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Jul-14-23 04:01PM Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update (Business Wire) +7.94%
May-26-23 04:01PM Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives (Business Wire)
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DGP Co., Ltd.10% OwnerFeb 29 '24Sale1.323,400,0004,488,0000Mar 04 06:36 PM
12
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.